OBJECTIVE -Our aim was to assess the risk of major amputation or death after leg bypass surgery for critical limb ischemia in patients with diabetes versus those without. CONCLUSIONS -Diabetes is associated with lower amputation-free survival after leg bypass for critical limb ischemia. Patients with diabetes and limb ischemia need intensified treatment of diabetes-related risk factors to improve outcome.
D
iabetes is a common cause of mortality and morbidity, largely due to a fourfold increase in cardiovascular disease in those with diabetes (1). The effect of diabetes seems especially pronounced for peripheral arterial disease (PAD) and lower-limb amputations (2). Most nontraumatic lower-limb amputations in the Western world are performed on patients with diabetes, whose relative risk of major amputation is 12-to 24-fold compared with that for patients without diabetes (3). Amputations in patients with diabetes are usually preceded by critical limb ischemia (4). The prevalence of diabetes among patients with leg bypass surgery for critical limb ischemia varies between 30 and 80% (5), whereas the prevalence of diabetes in comparable agegroups in the population is ϳ10%. Patients with critical limb ischemia commonly require leg bypass surgery to distal arteries to prevent major amputation.
Inferior outcome after leg bypass surgery could partly explain the higher amputation and mortality rates in patients with diabetes, but there is no standard for reporting outcome after lower-limb vascular reconstruction. Outcome is predominately reported as the proportion of limbs without amputation (limb salvage) at different times after the vascular procedure. This is a problematic and not always relevant measure in an elderly population with high mortality. Patients with the highest risk for amputation may die shortly after vascular reconstruction, and diabetes per se will increase that risk. Thus, by focusing on the fate of the limb the fate of the patient will be more or less neglected and is better evaluated by amputation-free survival.
There is an abundance of observational studies on this issue; some reported excellent results after leg arterial bypass surgery with no difference between patients with and without diabetes (6 -8), whereas others have found results to be worse in patients with diabetes (9 -11). Most of these studies are single-center studies from referral centers and are associated with inconsistencies and methodological problems, making it difficult to draw conclusions from results for patients with diabetes.
Population-based studies on the outcome after infrainguinal revascularization in patients with diabetes and critical limb ischemia are lacking. Indirect data from other population-based studies, including patients with various degrees of lower-limb ischemia and a broad range of vascular interventions, suggest either equal (12) or worse (13, 14) outcome for patients with diabetes. The conclusion of most reports, however, is that diabetes does not negatively influence the long-term outcome of lower-limb revascularization (5).
Data on this issue are important because they could promote the understanding of both diabetes and critical limb ischemia and provide further insight into the clinical course of patients with diabetes.
Bearing in mind the generally elevated risk for amputation and mortality in patients with diabetes, we postulated that diabetes decreases amputation-free survival after leg bypass surgery for critical ischemia. To assess this hypothesis we undertook a nationwide populationbased cohort study of outcome after leg bypass surgery in a well-defined high-risk population with critical limb ischemia. We compared diabetic patients with nondiabetic patients and determined amputation-free survival time.
RESEARCH DESIGN AND METHODS -The patient cohort was established using the Swedish Vascular Registry (Swedvasc). Outcomes were assessed by linking this cohort with the National Hospital Patient Registry (NHPR) and the Cause-of-Death Registry (CDR) in Sweden. Unambiguous record linkage between all registries is possible through use of the unique personal identification number assigned to all Swedish residents.
Swedvasc is a population-based, vascular surgery registry covering more than 95% of all arterial vascular procedures performed in the Swedish population (8.5 million) and containing detailed, prospectively registered information on indications, risk factors, and surgical procedures for each individual (15 To study amputation-free survival, we designated our primary outcome as ipsilateral amputation, defined as first amputation above the ankle (i.e., major amputation) in the limb on which bypass was performed (i.e., ipsilateral limb), or death from any cause-whichever occurred first. The observation period began on the index date and continued until the primary outcome event occurred or, if no event occurred, until 31 December 2005. Secondary outcomes were death from any cause and first amputation irrespective of side.
We assessed amputation status and survival status by linking each patient by their personal identification number to the NHPR and CDR databases, respectively. Amputation above the ankle was defined as a discharge record after index date with NCSP code NFQ09 (hip exarticulation), NFQ19 (transfemoral amputation), NGQ09 (knee exarticulation), or NGQ19 (transtibial amputation). We ascertained each amputation found in NHPR by retrieving medical records from the surgical procedure. We checked that level and date for amputation were correct and recorded information on which side the amputations was done.
Earlier validation of the Swedvasc database has shown over 90% accuracy of variables (15) . We performed further validation with a randomly selected sample of 140 patients (7.6%) from the study cohort. Data from Swedvasc were compared with corresponding medical records to assess agreement for operative details and risk factors. We calculated sensitivity, specificity, and accuracy with patient charts used as standard (see the online appendix available at http://dx.doi.org/ 10.2337/dc07-2424). The accuracy was over 90% for all variables except cardiac disease, hypertension, and pulmonary disease. While examining the diabetes variable, we found that two hospitals accounted for 77 out of 146 (53%) of missing values. Having checked the medical records relating to the hospitalization for the bypass procedure of these 77 patients, 73 were considered not to have diabetes. The remaining 70 (3.8%) patient records left with missing values for diabetes status in the final cohort were assumed to correspond with individuals without diabetes in analyses.
Our study required a sample size of ϳ800 patients with diabetes according to a power calculation based on a 90% probability that the study would detect an outcome difference between patients with and without diabetes at a two-sided 5% significance level, an assumed true hazard ratio (HR) of 1.2, and an accrual period of 3 years.
Cumulative event rates and survival curves were calculated with the KaplanMeier method, with the index date as time zero. We compared patients with diabetes to patients without known diabetes by calculating the crude HR for primary outcome using a Cox proportional hazards model; we subsequently adjusted the HR for prespecified potential confounders: age at index operation, sex, severity of limb ischemia, level of distal anastomosis (popliteal artery below knee, crural vessels, or pedal artery), type of graft (use of patient's own vein or not), pulmonary disease, and smoking (ongoing or quit less than 5 years ago). We performed prespecified sex subgroup analysis and estimated interaction effects according to the methodology of Andersson et al. (17) . Age was entered as a continuous variable, and all other variables were entered as dichotomous variables in the adjusted models.
We also evaluated the influence of several risk factors assumed to be in the causal pathway to diabetes complications, including renal disease (serum creatinine Ͼ150 mmol/l), cardiac disease (previous myocardial infarction, angina pectoris, atrial fibrillation, heart failure, ischemic signs on electrocardiogram, or previous heart surgery), hypertension, and cerebrovascular disease (stroke or transient ischemic attack). These factors were not regarded as confounders.
We used secondary outcome measures to test the robustness of our findings. First, we extended the outcome event to also include contralateral amputations in the amputation-free survival end point. Second, we repeated the analysis for limb salvage by censoring for death to ascertain that any associations found in amputation-free survival were not an effect of different mortality rates between patients with and without diabetes.
Both visual inspection of log-log plots and a supremum test based on Schoenfeld residuals (P ϭ 0.61) indicated that the proportional-hazard assumption was not violated. All HRs were reported with 95% CI, and all tests were two tailed with a P value of 0.05 judged statistically significant. The study was approved by the research ethics committee at Karolinska Institutet, Stockholm, Sweden.
RESULTS -During the 3-year accrual period, we identified 6,869 patients in whom vascular procedures were performed and whose lower-limb ischemia manifested as rest pain or tissue loss. Of these patients, we selected individuals who had their first unilateral leg bypass operation to an artery below the knee, yielding a final cohort of 1,840 patients-742 with and 1,098 without diabetes. Patients with diabetes were younger (73.9 vs. 77.8 years; P Ͻ 0.0001), and a higher proportion of patients with diabetes had tissue loss (82 vs. 67%) than those without diabetes. Demographic, procedural, and risk factors recorded in connection with surgery are listed in Table 1 . Cardiac disease and renal insufficiency were more common in patients with diabetes than in those without (65 vs. 55% and 20 vs. 8%, respectively), whereas smoking and pulmonary disease were more prevalent in patients without diabetes. Other factors were similarly distributed in patients with and without diabetes.
The median duration of follow-up was 2.2 years, equivalent to 4,015 person-years of observation. The shortest event-free follow-up was 2 years and the longest 4.9 years. A total of 446 patients with diabetes and 558 without underwent ipsilateral amputation or died, giving a total of 1,004 outcome events. The rate of ipsilateral amputation or death per 100 person-years was higher in patients with diabetes (30.2 [95% CI 26.6 -34.2]) than in patients without (22.0 [19.4 -24 .9]). Almost one-half of the patients with diabetes and one-third of those without had lost their leg or were deceased 2 years after index procedure (Fig. 1) . The median time to this event was 2.3 years (95% CI 1.9 -2.8) in patients with diabetes and 3.4 years (3.1-3.7) in those without.
The crude and age-adjusted HRs for ipsilateral amputation or death for patients with diabetes compared with patients without diabetes were 1.32 (95% CI 1. 17 CONCLUSIONS -W e o b s e r v e d that patients with diabetes had a 55% increase in the risk for major amputation or death after leg bypass surgery for critical lower-limb ischemia compared with patients without diabetes. On average, patients with diabetes had 1 less year to live without amputation. The apparent reduction in amputation-free survival for patients with diabetes was also evident after controlling for confounding factors. Further adjustments for intermediate factors did not influence results substantially. Moreover, similar results were obtained when using the secondary end points survival, limb salvage, and any major amputation irrespective of side. Our findings also emphasize that the rate of major amputation and death after vascular reconstruction is high in patients with critical limb ischemia, both for patients with and without diabetes (18) . This is the first nationwide population-based study of amputation-free survival after leg vascular reconstruction for critical limb ischemia comparing patients with and without diabetes. We believe for a number of reasons that our results are likely to be a proper estimate of amputation-free survival after leg bypass. First, (13) Data are means Ϯ SD or n (%).
we used nationwide data with complete coverage for identification of the cohort, thereby minimizing selection bias. Referral and diagnostic bias are also almost completely avoided in a setting with a national health care service that provides free access to health care. Second, diabetes diagnosis was found to have a sensitivity of 96% and a specificity of 99%. Third, we were able to achieve complete and accurate follow-up of amputation status and death using nationwide registry data. Moreover, our cohort consisted exclusively of patients with critical ischemia undergoing distal bypass surgery, thus avoiding confounding due to the inclusion of patients with less severe degrees of ischemia or more proximal procedures. Our results seem plausible considering the substantial body of evidence of increased cardiovascular risk (1) and markedly elevated risk for amputation (3) in patients with diabetes. The difference between our results and those obtained from numerous case series (5) showing equal outcome in patients with and without diabetes is most likely explained by different outcome measures (i.e., limb salvage instead of amputation-free survival) by inclusion of younger patients and patients with less severe degrees of ischemia.
Several studies have examined factors contributing to postoperative amputation and mortality in patients with and without diabetes, but all have specific limitations such as including only patients with diabetes, small sample size, short or incomplete follow-up, combined analysis of patients with claudication and critical limb ischemia, supra-and infrainguinal procedures, and inability to distinguish between ipsilateral and contralateral am- putations (12, 14) . All these factors have a profound effect on outcome after leg bypass surgery. We found only one population-based study aiming to investigate outcome after vascular procedures for critical limb ischemia in patients with and without diabetes (12) . This study found higher amputation rates in patients with diabetes, but patients were only followed for 30 days.
As a result of the scarce use of amputation-free survival as outcome measure in contemporary case series and trials, we found it difficult to compare our results with those from these studies. The short duration of amputation-free survival in our study is in accordance with the overall amputation-free survival of the BASIL (Bypass Versus Angioplasty in Severe Ischemia of the Leg) trial (55% at 3 years) and in the Veterans Affairs National Surgical Quality Improvement Program (57% at 3 years), which recruited participants comparable with our cohort in terms of age distribution and proportion of patients with diabetes (9,18).
Our results indicate that the impact of diabetes on amputation-free survival is more pronounced in male compared with female patients. Other studies support this finding regarding PAD outcome (14) and amputations (19) . Biological differences, including delayed onset of cardiovascular disease in women, may perhaps explain this effect. According to a 2004 population-based study of PAD in Sweden, the prevalence of critical limb ischemia is higher among women (20) . This higher prevalence is not reflected in our cohort, suggesting a relative underuse of revascularization in women; a selection bias of healthier women for revascularization could explain our observed better outcome in women.
There are several limitations to this study that merit discussion. The observational design might have permitted uncontrolled confounding factors to affect the results. A second limitation involves our definition of diabetes, which is based on clinical overt disease reported to Swedvasc. We therefore did not identify individuals with undiagnosed diabetes. The risks for cardiovascular events or death and amputation are elevated in patients with undiagnosed diabetes (21, 22) . Thus, the possible misclassification of exposure would lead to falsely high estimates of amputation and death in our reference group without diabetes, biasing our results toward the null hypothesis. Finally, we were also unable to distinguish between type 1 and type 2 diabetes. As the risk for amputation (23) and the risk for cardiovascular death (24) are approximately equal in type 1 and 2 diabetes, this limitation has probably not affected our results.
The impact of diabetes on cardiovascular disease is greater than can be explained by higher prevalence of traditional atherosclerotic risk factors (2). Several mechanisms coupled with hyperglycemia have been shown to augment the atherosclerosis process. Activation of the protein kinase C pathway by hyperglycemia seems to be an important initial step leading to oxidative stress and endothelial dysfunction (25) . Hyperglycemia also induces formation of advanced glycation end products and upregulates the receptor for advanced glycation end products, activation of which has multiple effects in vascular tissue; it is proinflammatory, augments smooth muscle migration and proliferation, and causes endothelial dysfunction and oxidative stress (25) . Diabetes is also characterized by distinctive atherogenic lipid disturbances, increased platelet activation, and a hypercoagulable state (25) . These are all potentially modifiable mechanisms, pointing to the possibility that improved glucose control and targeted therapies could improve outcome after vascular reconstruction in patients with diabetes.
An additional explanation of our findings is the high proportion of tissue loss in patients with diabetes and lower-limb ischemia, which may indicate an undue delay in recognition of ischemia. This delay is probably explained by masking of ischemic symptoms from concomitant peripheral neuropathy (2).
Our findings might have consequences for aspects of patient care. Patients with diabetes presenting with limb ischemia should be treated as having very high mortality risk and require intense treatment of cardiovascular risk factors at the earliest possible stage.
In summary, diabetes diminishes the chances of survival and of avoiding amputation in patients with critical lower limb ischemia undergoing leg bypass procedures. Further studies in this group of patients should be directed to find ways to reduce this excess risk.
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